MRA Advisory Group Makes New Investment in GeneDx Holdings Corp. $WGS

Key Points

• MRA Advisory Group has acquired a new stake in GeneDx Holdings Corp., purchasing 3,229 shares valued at approximately $298,000 during the 2nd quarter.
• GeneDx's stock price recently opened at $123.95, and the company has experienced significant volatility, with a 12-month low of $35.88 and a high of $136.00.
• Analysts have adjusted their price targets for GeneDx, with recommendations ranging from an "equal weight" rating at $95.00 by Wells Fargo to a target of $140.00 by Piper Sandler, indicating a consensus rating of "Moderate Buy".

MRA Advisory Group acquired a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 3,229 shares of the company's stock, valued at approximately $298,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Lazard Asset Management LLC bought a new position in GeneDx in the fourth quarter valued at $35,000. GAMMA Investing LLC increased its stake in shares of GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after purchasing an additional 264 shares in the last quarter. Comerica Bank bought a new position in GeneDx in the 4th quarter worth $50,000. US Bancorp DE boosted its holdings in shares of GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after purchasing an additional 548 shares during the last quarter. Finally, KBC Group NV purchased a new stake in GeneDx in the 1st quarter worth about $81,000. Institutional investors own 61.72% of the company's stock.

GeneDx Stock Down 1.5%

Shares of NASDAQ WGS opened at $123.95 on Monday. GeneDx Holdings Corp. has a 12-month low of $35.88 and a 12-month high of $136.00. The stock has a market cap of $3.56 billion, a PE ratio of 2,479.00 and a beta of 2.03. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $107.63 and a 200 day moving average of $91.88.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The company had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Guggenheim restated a "buy" rating and set a $115.00 target price (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Finally, Piper Sandler lifted their price objective on shares of GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Thursday. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $104.13.

Insider Buying and Selling at GeneDx

In other GeneDx news, Director Jason Ryan sold 38,072 shares of the business's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the transaction, the director directly owned 103,284 shares in the company, valued at $13,148,053.20. The trade was a 26.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Kevin Feeley sold 378 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $125.81, for a total transaction of $47,556.18. Following the completion of the transaction, the chief financial officer owned 4,096 shares in the company, valued at $515,317.76. The trade was a 8.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 561,641 shares of company stock worth $67,551,904 in the last 90 days. 29.60% of the stock is currently owned by insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.